nach oben

European Surgery

Erschienen in:

01.02.2013 | Original Article

The minimal dose of FK506 is sufficient to facilitate the arterialisation of venous allografts in rats

verfasst von: M. Varga, MD, I. Matia, A. Lodererova, M. Adamec

Erschienen in: European Surgery | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Summary

Background

We investigated whether a minimal dose of FK506 is sufficient to inhibit the rejection of venous allografts and facilitate allograft adaptation to arterialisation in rats.

Methods

Iliolumbar veins from Brown Norway (BN) rats were transplanted into the abdominal aorta of Lewis (LEW) rats. Recipient animals received daily intramuscular injections of 0.1 mg kg⁻ ¹ FK506. Light microscope evaluations of grafts were performed 30 days after transplantation. We investigated the presence of endothelial cells, the intensity of intimal proliferation, the deposition of immunoglobulin G molecules into the medial layer and the degree of adventitial infiltration by Lewis MHC class II-positive, CD4-positive and CD8-positive cells. All results were compared to previously reported data for syngeneic, allogeneic non-immunosuppressed and allogeneic FK506-low-dose immunosuppressed animals.

Results

All alloveins under minimal FK506 immunosuppression showed typical histological signs of arterialisation 30 days after transplantation. Intimal thickness (15.1 ± 6.1 mm) and the degree of adventitial infiltration by MHC class II-positive (16.96 ± 10.46), CD8-positive (2.63 ± 2.6), and CD4-positive (7.67 ± 8.29) cells were not significantly different when compared to untreated syngeneic veins and allogeneic veins treated with a low dose of FK506, respectively.

Conclusions

Even the minimal dose of FK506 was sufficient to inhibit the acute rejection of venous allografts and to facilitate allograft arterialisation 30 days after transplantation.

Vorheriger Artikel Incidence of ischemic type biliary lesions after liver transplantation using piggyback technique and retrograde reperfusion

Nächster Artikel Importance of ineffective esophageal motility in patients with erosive reflux disease on the long-term outcome of Nissen fundoplication

Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19 Suppl A:Si-xxviii, S1–250.

Randon C, Jacobs B, De Ryck F, Beele H, Vermassen F. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010;51(4):869–77.PubMedCrossRef

Matia I, Janousek L, Marada T, Adamec M. Cold-stored venous allografts in the treatment of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2007;34(4):424–31.PubMedCrossRef

Brockbank KG, McNally RT, Walsh KA. Cryopreserved vein transplantation. J Card Surg. 1992;7(2):170–6.PubMedCrossRef

Posner MP, Makhoul RG, Altman M, Kimball P, Cohen N, Sobel M, et al. Early results of infrageniculate arterial reconstruction using cryopreserved homograft saphenous conduit (CADVEIN) and combination low-dose systemic immunosuppression. J Am Coll Surg. 1996;183(3):208–16.PubMed

Matia I, Lodererova A, Adamec M. Delayed administration of FK 506 is sufficient to suppress acute rejection changes after aortal transplantation in rats. Transpl Int. 2007;20(4):371–80.PubMedCrossRef

Matia I, Varga M, Lodererova A, Adamec M. The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats. Eur J Vasc Endovasc Surg. 2010;39(4):478–84.PubMedCrossRef

Azuma N, Sasajima T, Kubo Y. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. J Vasc Surg. 1999;29(4):694–702.PubMedCrossRef

Kwei S, Stavrakis G, Takahas M, Taylor G, Folkman MJ, Gimbrone MA Jr, et al. Early adaptive responses of the vascular wall during venous arterialization in mice. Am J Pathol. 2004;164(1):81–9.PubMedCrossRef

10.

Westerband A, Crouse D, Richter LC, Aguirre ML, Wixon CC, James DC, et al. Vein adaptation to arterialization in an experimental model. J Vasc Surg. 2001;33(3):561–9.PubMedCrossRef

11.

Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330(20):1431–8.PubMedCrossRef

12.

Axthelm SC, Porter JM, Strickland S, Baur GM. Antigenicity of venous allografts. Ann Surg. 1979;189(3):290–3.PubMedCrossRef

13.

Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Posttransplant antibodies and fresh venous allograft failure in dogs. Transplantation. 1994;58(5):537–42.PubMedCrossRef

14.

Stevens SL, Tyler JD, Freeman MB, Hopkins F, Lewis T, Bray J, et al. Factors affecting patency of venous allografts in miniature swine. J Vasc Surg. 1990;12(3):361–6.PubMed

15.

Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg. 1995;110(6):1732–44.PubMedCrossRef

16.

Carpenter EW, Lindenauer SM. Immunosuppression in arterial and venous allografts. Arch Surg. 1973;106(1):77–8.PubMedCrossRef

17.

Mingoli A, Edwards JD, Feldhaus RJ, Hunter WJ 3rd, Naspetti R, Cavallari N, et al. Fresh vein allograft survival in dogs after cyclosporine treatment. J Surg Res. 1996;62(1):95–102.PubMedCrossRef

18.

Perloff LJ, Reckard CR, Rowlands DT Jr, Barker CF. The venous homograft: an immunological question. Surgery. 1972;72(6):961–70.PubMed

19.

Vermassen F, Degrieck N, De Kock L, Goubeau J, Van Landuyt K, Noens L, et al. Immunosuppressive treatment of venous allografts. Eur J Vasc Surg. 1991;5(6):669–75.PubMedCrossRef

20.

Ricotta JJ, Collins GJ Jr, Rich NM, Reynolds DG. Failure of immunosuppression to prolong venous allograft survival. Arch Surg. 1980;115(1):99–101.PubMedCrossRef

21.

Bandlien KO, Toledo-Pereyra LH, MacKenzie GH, Choudhury SP, Cortez JA. Immunosuppression with cyclosporine. A new approach to improve patency of venous allografts. Arch Surg. 1983;118(7):829–33.PubMedCrossRef

22.

Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55(4):455–62.PubMed

23.

Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M. In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation. 1997;63(7):1037–9.PubMedCrossRef

24.

Miller VM, Bergman RT, Gloviczki P, Brockbank KG. Cryopreserved venous allografts: effects of immunosuppression and antiplatelet therapy on patency and function. J Vasc Surg. 1993;18(2):216–26.PubMedCrossRef

25.

Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation. 2002;73(5):775–82.PubMedCrossRef

Titel: The minimal dose of FK506 is sufficient to facilitate the arterialisation of venous allografts in rats
verfasst von: M. Varga, MD
I. Matia
A. Lodererova
M. Adamec
Publikationsdatum: 01.02.2013
Verlag: Springer Vienna
Erschienen in: European Surgery / Ausgabe 1/2013
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI: https://doi.org/10.1007/s10353-012-0179-3

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

A duodenal stromal tumor mimicking a pancreatic head tumor: one case report and literature review

General surgery with qualities: sub the speciality

Innovation in esophageal surgery: be effective

Incidence of ischemic type biliary lesions after liver transplantation using piggyback technique and retrograde reperfusion

Clinical outcome after stapled transanal rectal resection for obstructed defecation syndrome: the first Iranian experience

Conservative treatment of abdominal compartment syndrome after large ventral hernia repair